1. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, van Hagen M, Postema PT, de Jong M, Reubi JC et al (1993) Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1,000 patients. Eur J Nucl Med 20(8):716–731
2. Lebtahi R, Cadiot G, Sarda L, Daou D, Faraggi M, Petegnief Y, Mignon M, le Guludec D (1997) Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 38(6):853–858
3. Chiti A, Briganti V, Fanti S, Monetti N, Masi R, Bombardieri E (2000) Results and potential of somatostatin receptor imaging in gastroenteropancreatic tract tumours. Q J Nucl Med 44(1):42–49
4. Ricke J, Klose KJ, Mignon M, Oberg K, Wiedenmann B (2001) Standardisation of imaging in neuroendocrine tumours: results of a European delphi process. Eur J Radiol 37(1):8–17
5. Schillaci O, Scopinaro F, Danieli R, Angeletti S, Tavolaro R, Annibale B, Cannas P, Marignani M, Colella AC, Delle Fave G (1997) Single photon emission computerized tomography increases the sensitivity of indium-111-pentetreotide scintigraphy in detecting abdominal carcinoids. Anticancer Res 17(3B):1753–1756